Gates Foundation buys stock to help develop malaria therapy component
By Devika Patel
Knoxville, Tenn., April 11 – Amyris, Inc. settled a $5 million private placement of stock with the Bill & Melinda Gates Foundation on April 8, according to an 8-K filed Monday with the Securities and Exchange Commission.
The company sold 4,385,964 common shares at $1.14 per share, which is an 8.57% premium to the April 7 closing share price of $1.05, and is also equal to the average of the daily closing price of the stock for the 20 trading days ending on April 7, the company noted in the filing.
Proceeds must be used to develop a yeast strain that produces artemisinic acid or amorphadiene at a low cost and supply these to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria.
Emeryville, Calif.-based Amyris is a maker of renewable chemicals and fuels.
| Issuer: | Amyris, Inc.
|
| Issue: | Common shares
|
| Amount: | $5 million
|
| Shares: | 4,385,964
|
| Price: | $1.14
|
| Warrants: | No
|
| Investor: | Bill & Melinda Gates Foundation
|
| Settlement date: | April 8
|
| Stock symbol: | Nasdaq: AMRS
|
| Stock price: | $1.05 at close April 7
|
| Market capitalization: | $262.18 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
